Leijun Hu

发表

A Randomized, Double‐Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density

R. Recker, S. Myers, B. Mitlak, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus.

R. Hansen, R. Fleischmann, J. McColm, 2016, British journal of clinical pharmacology.

Single‐ and Multiple‐Dose Randomized Studies of Blosozumab, a Monoclonal Antibody Against Sclerostin, in Healthy Postmenopausal Women

A. Chiang, J. McColm, Leijun Hu, 2014, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Effect of blosozumab on bone mineral density: results of a phase 2 study of postmenopausal women with low bone mineral density

R. Recker, B. Mitlak, A. Chiang, 2013 .

Population pharmacokinetic/pharmacodynamic assessment of pharmacological effect of a selective estrogen receptor β agonist on total testosterone in healthy men

Leijun Hu, A. Borel, Yan Jin, 2015, Clinical pharmacology in drug development.

Dose‐dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor

J. Henck, J. Uetrecht, T. McNearney, 2018, British journal of clinical pharmacology.

Computational Modeling to Predict Effect of Treatment Schedule on Drug Delivery to Prostate in Humans

J. Au, M. Wientjes, Leijun Hu, 2007, Clinical Cancer Research.

Bladder Tissue Pharmacokinetics of Intravesical Mitomycin C and Suramin in Dogs

J. Au, M. Wientjes, Leijun Hu, 2010, The AAPS Journal.

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

S. Studenski, C. Becker, S. Lord, 2015, The lancet. Diabetes & endocrinology.

Suramin pharmacokinetics after regional or systemic administration

Leijun Hu, 2005 .

A randomized clinical efficacy study targeting mPGES1 or EP4 in dogs with spontaneous osteoarthritis

M. J. Fisher, P. Liu, M. Warner, 2019, Science Translational Medicine.

Safety of the antimyostatin monoclonal antibody LY2495655 in healthy subjects and patients with advanced cancer.

David A. Smith, M. Benson, G. Weiss, 2012 .

LY3127760, a Selective Prostaglandin E4 (EP4) Receptor Antagonist, and Celecoxib: A Comparison of Pharmacological Profiles

X. Yang, T. McNearney, W. Landschulz, 2017, Clinical and translational science.

Abstract CT018: Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents

Y. Bang, A. Patnaik, J. Bendell, 2018, Clinical Trials.

Intraprostatic Chemotherapy: Distribution and Transport Mechanisms

J. Au, M. Wientjes, Jenny H. Zheng, 2005, Clinical Cancer Research.

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

R. Recker, B. Mitlak, Toshio Matsumoto, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Issues, challenges, and opportunities in model-based drug development for monoclonal antibodies.

R. Hansen, Leijun Hu, Ryan J Hansen, 2013, Journal of pharmaceutical sciences.

The Effect of Discontinuing Treatment With Blosozumab: Follow‐up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density

R. Recker, B. Mitlak, Toshio Matsumoto, 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.